Every 10-Q that Context Therapeutics Inc. (CNTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CNTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNTX filings page.
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies CTIM-76 and CT-202 for solid tumors. CTIM-76 has FDA Fast Track designation in platinum-resistant ovarian cancer, CT-202 is entering a first-in-human trial, and internal development of CT-95 has been discontinued to focus resources on these programs.
For the six months ended June 30, 2026, the company reported a net loss of $23.2 million, mainly due to higher research and development spending, including a $6.5 million payment under the BioAtla license amendment for CT-202 and increased clinical activity across CTIM-76, CT-95 and CT-202. There was no product revenue.
Cash and cash equivalents were $43.0 million as of June 30, 2026, which management expects will fund operations into the fourth quarter of 2027. The accumulated deficit reached $154.1 million, and the company plans to pursue additional financing, including potential at-the-market equity sales, to support ongoing development and any future commercialization.
Context Therapeutics Inc. reported a Q1 2026 net loss of $8.7 million, wider than the prior year, driven by higher research and development spending on its three T cell engaging antibody programs CTIM-76, CT-95 and CT-202. Research and development expenses reached $7.0 million, with growing clinical and manufacturing costs as CTIM-76 and CT-95 advance through Phase 1 trials and CT-202 moves toward first-in-human dosing. General and administrative costs were $2.3 million. The company ended March 31, 2026 with $54.5 million in cash and cash equivalents and an accumulated deficit of $139.6 million, and expects existing cash to fund operations into mid-2027 while it progresses early-stage clinical trials.
Context Therapeutics (CNTX) reported Q3 2025 results showing continued investment in its T‑cell engager pipeline and a narrower quarterly loss. Net loss was $9,693,237 versus $17,459,893 a year ago, as research and development declined year over year. Cash and cash equivalents were $76,938,183 as of September 30, 2025, supporting operations the company indicates extend into 2027.
R&D expense was $8,722,104, driven by CT‑202 manufacturing and preclinical work and ongoing trials for CTIM‑76 and CT‑95; general and administrative was $1,888,376. The company dosed first patients in CTIM‑76 (January 2025) and CT‑95 (April 2025) Phase 1 studies and plans to share initial readouts in 2026. In October 2025, CNTX achieved a $2,000,000 development milestone under the BioAtla agreement, and on November 3, 2025, it entered a CT‑202 license with Lonza covering manufacturing IP.
Capital resources include an amended at‑the‑market facility filed on October 24, 2025 permitting sales of up to $75,000,000 of common stock (exclusive of shares sold in 2024). Shares outstanding were 91,879,177 as of November 4, 2025.